What sorts of imaging techniques are used to measure amyloid aggregates in the brain? What do we know about the relationship between symptoms of Alzheimer’s disease and amyloid levels that are detected through neuroimaging?

With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on Alzheimer’s disease, the amyloid hypothesis, disease modification, and breakthroughs in diagnosis and treatment.

Today, Dr. Andy Cutler interviews Dr. Lon Schneider on biomarkers for Alzheimer’s disease and treatments that target amyloid.

Lon Schneider, MD, MS is Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California. He is director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center and co-director of the clinical core of the University of Southern California Alzheimer's Disease Research Center (National Institutes of Health). In addition, he is principal investigator of the National Institute of Mental Health's CATIE program, a multicenter effectiveness trial of atypical antipsychotics in Alzheimer's disease.

Let’s listen in to Part 2 of our theme: Biomarkers and Treatments that Target Amyloid

Subscribe to the NEI Podcast, so that you don’t miss another episode!

E175 - The PsychopharmaStahlogy Show: Alzheimer’s Disease: Biomarkers and Treatments that Target Amyloid 01:00:44 Share

NEI Podcast

Shownotes Transcript

E175 - The PsychopharmaStahlogy Show: Alzheimer’s Disease: Biomarkers and Treatments that Target Amyloid